

Global Pharmacovigilance

The Global Pharmacovigilance Department is responsible for the collection, processing and analysis of adverse events for Mallinckrodt's pharmaceutical products in compliance with regulatory requirements. The goals of the Global Pharmacovigilance Department are to minimize or prevent harm to patients by identifying new safety concerns and/or hazards associated with Mallinckrodt medicinal products and to implement risk-minimization measures when appropriate. You may contact Global Pharmacovigilance as follows to report any side effect / adverse drug experience:

Region /Country	Product	Contact Details
Asia Pacific	UVADEX	ecphelp@therakos.com
Asia Pacific	INOMAX / INOflo	safety-inotherapy@mallinckrodt.com
Asia Pacific	All products except UVADEX and INOMAX/INOflo	mallinckrodt@professionalinformation.co.uk +800 44 55 2221
Canada	INOMAX / UVADEX	877 566 9466
Canada	Methadose	PVgenerics@mallinckrodt.com 1855-399-6742
Canada	All products except UVADEX, INOMAX and Methadose	globalpv@mallinckrodt.com 1855-399-6742
Europe	UVADEX	<i>By language</i> English: +44 154 860 0009 French: +33 182 880 867 German: +49 322 2109 3619 Spanish: +34 932 202 094

		Italy: +39 051 042 0666 ecphelp@therakos.com
Europe	All products except UVADEX	mallinckrodt@professionalinformation.co.uk (00) 800 55 444 777
Latin America	UVADEX	ecphelp@therakos.com
Latin America	INOMAX	safety-inotherapy@mallinckrodt.com
Latin America	All products except UVADEX and INOMAX	pv-latam@mallinckrodt.com
Mexico	INOMAX	+1 877 566 9466
Middle East	UVADEX	ecphelp@therakos.com
USA	UVADEX	877 566 9466
USA	INOMAX	877.566.9466
USA	Generics	PVgenerics@mallinckrodt.com 800 778 7898
USA	All products except UVADEX, INOMAX, and Generics	globalpv@mallinckrodt.com 800 778 7898